Molecular Partners AG ADR MOLN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MOLN is a good fit for your portfolio.
News
-
Life Science Cares Launches in Switzerland
-
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
-
Molecular Partners Publishes Invitation to Annual General Meeting 2024
-
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
-
Molecular Partners Announces Dismissal of Class Action Lawsuit
-
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
Trading Information
- Previous Close Price
- $3.88
- Day Range
- $3.88–3.88
- 52-Week Range
- $3.32–7.32
- Bid/Ask
- $3.61 / $4.00
- Market Cap
- $127.53 Mil
- Volume/Avg
- 254 / 3,069
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 16.24
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 167
Comparables
Valuation
|
Metric
|
MOLN
|
CRSP
|
FDMT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.61 | 2.29 | 3.29 |
Price/Sales | 16.24 | 11.54 | 44.43 |
Price/Cash Flow | — | — | — |
Price/Earnings
MOLN
CRSP
FDMT
Financial Strength
|
Metric
|
MOLN
|
CRSP
|
FDMT
|
|---|---|---|---|
Quick Ratio | 13.18 | 17.41 | 15.21 |
Current Ratio | 13.35 | 17.54 | 15.65 |
Interest Coverage | −1,947.91 | — | — |
Quick Ratio
MOLN
CRSP
FDMT
Profitability
|
Metric
|
MOLN
|
CRSP
|
FDMT
|
|---|---|---|---|
Return on Assets (Normalized) | −24.61% | −3.61% | −25.94% |
Return on Equity (Normalized) | −27.40% | −4.34% | −28.64% |
Return on Invested Capital (Normalized) | −28.86% | −3.83% | −31.25% |
Return on Assets
MOLN
CRSP
FDMT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qryjfgkqzz | Ctq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Prdkffzm | Pskch | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jflsvddf | Mtpfqqy | $97.8 Bil | |
MRNA
| Moderna Inc | Gppzlnbg | Kdz | $41.3 Bil | |
ARGX
| argenx SE ADR | Zqfhmyxbb | Dwzs | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nhghmfjh | Rfkd | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nftlhtjx | Ddkbrx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Krmccmph | Ppvggg | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pxrfspkd | Crttjp | $12.5 Bil | |
INCY
| Incyte Corp | Nwmqrbl | Pyqsw | $11.6 Bil |